Literature DB >> 8986436

Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter.

C J Ring1, J D Harris, H C Hurst, N R Lemoine.   

Abstract

In order to exploit the tumour-specific nature of ERBB2 expression for genetic prodrug-activation therapy, we have generated recombinant adenoviral, retroviral and plasmid vectors containing an expression cassette consisting of the ERBB2 promoter and herpes simplex virus thymidine kinase coding sequence. In the case of the adenoviral vectors, the expression cassette was introduced into the E1 or E3 region of the genome. All of the vectors were capable of sensitizing ERBB2-positive cells to the action of ganciclovir. In contrast to the retroviral and plasmid vectors, however, transduction with the adenoviral vectors also resulted in sensitization of ERBB2-negative cells to ganciclovir, infection of cell lines with a beta-galactosidase expressing adenovirus showed that the sensitizing effect was not due to adenoviral infection per as in all but one of the cell lines tested. This study demonstrates that the ERBB2 promoter can be used to induce ERBB2-dependent sensitization to ganciclovir when in the context of retroviral and plasmid vectors. Observations made in this study do, however, suggest that adenoviral vectors may not be the ideal system to engineer conditional expression, and possible explanation for this phenomenon are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8986436

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted.

Authors:  Masato Yamamoto; Julia Davydova; Koichi Takayama; Ramon Alemany; David T Curiel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro.

Authors:  Shuhong Hao; Xiaoyuan Du; Yang Song; Ming Ren; Qiwei Yang; Ao Wang; Qingyu Wang; Haiyue Zhao; Zhenwu Du; Guizhen Zhang
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 3.  Direct cell killing by suicide genes.

Authors:  L A Martin; N R Lemoine
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

4.  Variables affecting in vivo performance of high-capacity adenovirus vectors.

Authors:  Gudrun Schiedner; Sabine Hertel; Marion Johnston; Volker Biermann; Volker Dries; Stefan Kochanek
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element.

Authors:  R P Haberman; T J McCown; R J Samulski
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 6.  The potential for gene therapy in pancreatic cancer.

Authors:  M J Humphreys; W Greenhalf; J P Neoptolemos; P Ghaneh
Journal:  Int J Pancreatol       Date:  1999-08

Review 7.  Prodrugs for improving tumor targetability and efficiency.

Authors:  Rubi Mahato; Wanyi Tai; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2011-02-17       Impact factor: 15.470

8.  Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.

Authors:  Mariam A Stoff-Khalili; Angel A Rivera; Ana Nedeljkovic-Kurepa; Arrigo DeBenedetti; Xiao-Lin Li; Yoshinobu Odaka; Jagat Podduturi; Don A Sibley; Gene P Siegal; Alexander Stoff; Scott Young; Zheng B Zhu; David T Curiel; J Michael Mathis
Journal:  Breast Cancer Res Treat       Date:  2007-05-17       Impact factor: 4.872

9.  In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter.

Authors:  Agustín Luz-Madrigal; Carmen Clapp; Jorge Aranda; Luis Vaca
Journal:  Virol J       Date:  2007-09-18       Impact factor: 4.099

10.  Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer.

Authors:  Eiji Toyoda; Ryuichiro Doi; Kazuhiro Kami; Tomohiko Mori; Daisuke Ito; Masayuki Koizumi; Atsushi Kida; Kazuyuki Nagai; Tatsuo Ito; Toshihiko Masui; Michihiko Wada; Masatoshi Tagawa; Shinji Uemoto
Journal:  J Exp Clin Cancer Res       Date:  2008-08-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.